AbbVie Says 36% of Crohn’s Trial Patients Achieved Endoscopic Remission on Skyrizi

AbbVie said 36% of patients with Crohn’s disease in a Phase 3 trial achieved endoscopic remission, defined as healing of the intestinal lining with little to no visible inflammation.